Factors associated with high antibody titer following coronavirus disease among 581 convalescent plasma donors: A single-center cross-sectional study in Japan

Suzuki, T.; Asai, Yasufumi; Ide, Satoshi; Fukuda, Saori; Tanaka, Akihito; Shimanishi, Yumiko; Takahashi, Kozue; Terada, Mari; Sato, Lubna; Sato, Mitsuhiro; Inada, Makoto; Yamada, Gen; Miyazato, Yusuke; Akiyama, Yutaro; Nomoto, Hidetoshi; Nakamoto, Takato; Nakamura, Keiji; Togano, Tomiteru; Morioka, Shigefumi; Kinoshita-Iwamoto, Noriko; Saito, Sho; Kutsuna, Satoshi; Ohmagari, Norio

doi:10.1016/j.jiac.2021.10.012

Cited by 5 publications

(10 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies identified several factors that may predict hightiter antibodies in CCP donors, including age (13)(14)(15)(16)(17), gender (13)(14)(15)18), race/ethnicity (13,19), BMI (20), complications (15), SARS-CoV-2 infection symptoms (14,16), illness severity (15), and time after infection (13,16,21). Identifying these predictive factors of high-titer CCP can assist in streamlining screening, allowing for more efficient fulfillment of clinical demands while also reducing screening costs.…”

Section: Introductionmentioning

confidence: 99%

Predictors of high SARS-CoV-2 immunoglobulin G titers in COVID-19 convalescent whole-blood donors: a cross-sectional study in China

et al. 2023

View full text Add to dashboard Cite

BackgroundDemographic information has been shown to help predict high antibody titers of COVID-19 convalescent plasma (CCP) in CCP donors. However, there is no research on the Chinese population and little evidence on whole-blood donors. Therefore, we aimed to investigate these associations among Chinese blood donors after SARS-CoV-2 infection.MethodsIn this cross-sectional study, 5,064 qualified blood donors with confirmed or suspected SARS-CoV-2 infection completed a self-reported questionnaire and underwent tests of SARS-CoV-2 Immunoglobulin G (IgG) antibody and ABO blood type. Logistic regression models were used to calculate odds ratios (ORs) for high SARS-CoV-2 IgG titers according to each factor.ResultsTotally, 1,799 participants (with SARS-CoV-2 IgG titers≥1:160) had high-titer CCPs. Multivariable analysis showed that a 10-year increment in age and earlier donation were associated with higher odds of high-titer CCP, while medical personnel was associated with lower odds. The ORs (95% CIs) of high-titer CCP were 1.17 (1.10–1.23, p< 0.001) and 1.41 (1.25-1.58, p< 0.001) for each 10-year increment in age and earlier donation, respectively. The OR of high-titer CCP was 0.75 (0.60-0.95, p = 0.02) for medical personnel. Female early donors were associated with increased odds of high-titer CCP, but this association was insignificant for later donors. Donating after 8 weeks from the onset was associated with decreased odds of having high-titer CCP compared to donating within 8 weeks from the onset, and the HR was 0.38 (95% CI: 0.22-0.64, p <0.001). There was no significant association between ABO blood type or race and the odds of high-titer CCP.DiscussionOlder age, earlier donation, female early donors, and non-medical-related occupations are promising predictors of high-titer CCP in Chinese blood donors. Our findings highlight the importance of CCP screening at the early stage of the pandemic.

show abstract

Section: Introductionmentioning

confidence: 99%

Predictors of high SARS-CoV-2 immunoglobulin G titers in COVID-19 convalescent whole-blood donors: a cross-sectional study in China

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Older age has been repeatedly observed as a risk factor of attenuated post-vaccination antibody titer in the previously naïve population ( 9 ). To the contrary, increasing age has been associated with stronger antibody responses in convalescent plasma donors ( 12 , 13 ). This can be explained by the fact that older individuals are more prone to symptomatic, and possibly more severe, SARS-CoV-2 infection, which in turn is often accompanied by a potentiated circulating IgG response ( 5 ).…”

Section: Discussionmentioning

confidence: 99%

Age-adjusted impact of prior COVID-19 on SARS-CoV-2 mRNA vaccine response

Nakagama¹,

Nakagama²,

Komase³

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

More people with a history of prior infection are receiving SARS-CoV-2 vaccines. Understanding the level of protection granted by ‘hybrid immunity’, the combined response of infection- and vaccine-induced immunity, may impact vaccination strategies through tailored dosing. A total of 36 infected (‘prior infection’) and 33 SARS-CoV-2 ‘naïve’ individuals participated. Participants provided sera six months after completing a round of BNT162b2 vaccination, to be processed for anti-spike antibody measurements and the receptor binding domain-ACE2 binding inhibition assays. The relationships between antibody titer, groups and age were explored. Anti-spike antibody titers at 6 months post-vaccination were significantly higher, reaching 13- to 17-fold, in the ‘prior infection’ group. Semi-log regression models showed that participants with ‘prior infection’ demonstrated higher antibody titer compared with the ‘naïve’ even after adjusting for age. The enhancement in antibody titer attributable to positive infection history increased from 8.9- to 9.4- fold at age 30 to 19- to 32-fold at age 60. Sera from the ‘prior infection’ group showed higher inhibition capacity against all six analyzed strains, including the Omicron variant. Prior COVID-19 led to establishing enhanced humoral immunity at 6 months after vaccination. Antibody fold-difference attributed to positive COVID-19 history increased with age, possibly because older individuals are prone to symptomatic infection accompanied by potentiated immune responses. While still pending any modifications of dosing recommendations (i.e. reduced doses for individuals with prior infection), our observation adds to the series of real-world data demonstrating the enhanced and more durable immune response evoked by booster vaccinations following prior infection.

show abstract

“…Finally, our findings do not support an association between antibody levels and ABO blood group. There is a clear association of blood group A with a higher risk and severity of COVID-19 [29][30][31], but the evidence of an association between ABO blood group and antibody levels are not clear in the literature [20,21,23].…”

Section: Discussionmentioning

confidence: 99%

“…In our series, donors over 40 years of age were more likely to have CP with high titres. Age has been described as a factor associated with antibody titres in several studies [20][21][22][23], including some large multivariate regression analyses that found a positive correlation with age even when adjusting the model by hospitalization history [24], and showed that the rate of antibody decline was significantly slower for donors over 55 years of age [25]. The reasons underlying the impact of age on anti-SARS-CoV-2 immune response are not clear [26], but some authors suggest that it may be linked to immunesenescence and the generation of immunoglobulins with lower antigen specificity in these patients [27].…”

Section: Discussionmentioning

confidence: 99%

Factors related to the development of high antibody titres against SARS‐CoV‐2 in convalescent plasma donors from the ConPlas‐19 trial

Romera Martínez,

Avendaño‐Solá,

Villegas Da Ros

et al. 2023

Vox Sanguinis

View full text Add to dashboard Cite

Background and ObjectivesThe efficacy of COVID‐19 convalescent plasma (CP) associates with high titres of antibodies. ConPlas‐19 clinical trial showed that CP reduces the risk of progression to severe COVID‐19 at 28 days. Here, we aim to study ConPlas‐19 donors and characteristics that associate with high anti‐SARS‐CoV‐2 antibody levels.Materials and MethodsFour‐hundred donors were enrolled in ConPlas‐19. The presence and titres of anti‐SARS‐CoV‐2 antibodies were evaluated by EUROIMMUN anti‐SARS‐CoV‐2 S1 IgG ELISA.ResultsA majority of 80.3% of ConPlas‐19 donor candidates had positive EUROIMMUN test results (ratio ≥1.1), and of these, 51.4% had high antibody titres (ratio ≥3.5). Antibody levels decline over time, but nevertheless, out of 37 donors tested for an intended second CP donation, over 90% were still EUROIMMUN positive, and nearly 75% of those with high titres maintained high titres in the second sample. Donors with a greater probability of developing high titres of anti‐SARS‐CoV‐2 antibodies include those older than 40 years of age (RR 2.06; 95% CI 1.24–3.42), with more than 7 days of COVID‐19 symptoms (RR 1.89; 95% CI 1.05–3.43) and collected within 4 months from infection (RR 2.61; 95% CI 1.16–5.90). Male donors had a trend towards higher titres compared with women (RR 1.67; 95% CI 0.91–3.06).ConclusionSARS‐CoV‐2 CP candidate donors' age, duration of COVID‐19 symptoms and time from infection to donation associate with the collection of CP with high antibody levels. Beyond COVID‐19, these data are relevant to inform decisions to optimize the CP donor selection process in potential future outbreaks.

show abstract

Factors associated with high antibody titer following coronavirus disease among 581 convalescent plasma donors: A single-center cross-sectional study in Japan

Cited by 5 publications

References 19 publications

Predictors of high SARS-CoV-2 immunoglobulin G titers in COVID-19 convalescent whole-blood donors: a cross-sectional study in China

Predictors of high SARS-CoV-2 immunoglobulin G titers in COVID-19 convalescent whole-blood donors: a cross-sectional study in China

Age-adjusted impact of prior COVID-19 on SARS-CoV-2 mRNA vaccine response

Factors related to the development of high antibody titres against SARS‐CoV‐2 in convalescent plasma donors from the ConPlas‐19 trial

Contact Info

Product

Resources

About